Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Smart intraoperativ påminnelse om å implementere sikkerhetsprinsipper i laparoskopisk kolecystektomi (CVS-Notifier)

16. november 2026 oppdatert av: IHU Strasbourg

CVS -Notifier - Smart intraoperativ påminnelse om å implementere sikkerhetsprinsipper i laparoskopisk kolecystektomi

The Critical View of Safety (CVS) is universally recommended to prevent bile duct injuries in laparoscopic cholecystectomy. However, CVS is underutilized and bile duct injuries are not decreasing. The CVS-Notifier SaMD (Software as a Medical Device) reminds surgeons to verify the CVS before dividing the cystic duct, as recommended by guidelines. It is hypothesized that this systematic and timely reminder could improve the implementation of CVS without disturbing surgical workflows.

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Detaljert beskrivelse

Laparoscopic cholecystectomy is the gold standard approach for the surgical removal of the gallbladder. However, between 0.3 and 1.5% of patients undergoing laparoscopic cholecystectomy experience a bile duct injury (BDI). This major complication translates into a threefold increase in mortality at 1 year, frequent medico-legal litigations, and an annual cost of about 1 billion dollars in the USA alone.

The visual perceptual illusion causing major BDIs can be prevented by implementing the Critical View of Safety (CVS). CVS consists of the clearance of the hepatocystic triangle from fat and connective tissue, the division of the lower part of the gallbladder from its liver bed, and ensuring that only two tubular structures-the cystic duct and the cystic artery-connected to the gallbladder are visible. Unfortunately, CVS implementation in surgical practices is as low as 9% and, in turn, BDIs do not decrease.

To improve the implementation of the CVS, multi-society consensus guidelines recommend to time-out to confirm CVS achievement before dividing cystic structures. A large quality improvement study demonstrated that a short time-out to recall CVS principles significantly increases CVS implementation rates. However, the implementation of the time-out and CVS decreases over time.

The CVS-Notifier SaMD reminds surgeons to time-out to verify the CVS before the division of the cystic duct. Such a systematic intraoperative reminder to implement best practices could help consistently perform safe laparoscopic cholecystectomies.

This first-in-human, exploratory study aims at evaluating the safety, usability, and potential impact of the CVS-Notifier SaMD in laparoscopic cholecystectomy.

The study is a single center, non-comparative, case series. Patients undergoing elective laparoscopic cholecystectomy who meet the eligibility criteria and express their consent to participate in the study will be enrolled. The CVS-Notifier SaMD will be installed on a medical grade computer connected to a secondary output of the laparoscopic video system (input) and to an auxiliary screen in the operating room (OR) (output). Surgeons will start the procedure as usual while the CVS-Notifier SaMD unobtrusively analyses the surgical video. When the beginning of the hepatocystic triangle dissection is detected, a visual reminder to verify CVS in an intraoperative time-out notification will appear on the auxiliary OR screen.

Surgeons and patients will be asked to fill in a survey to report their experience, after the procedure and before discharge, respectively.

Clinical, surgical, and device-related data will be collected and analyzed.

Studietype

Intervensjonell

Registrering (Faktiske)

41

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Strasbourg, Frankrike, 67000
        • Visceral and Digestive Surgery, Nouvel Hôpital Civil

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Man or woman over 18 years old.
  • Patient presenting with benign gallbladder disease requiring an elective laparoscopic cholecystectomy.
  • Patient without contraindications to anaesthesia or laparoscopic cholecystectomy surgery.
  • Patients capable of understanding and providing their written consent to the study.
  • Patient affiliated to the French social security system.

Exclusion Criteria:

  • Patients presenting with malignant gallbladder disease requiring an elective laparoscopic cholecystectomy.
  • Pregnant or lactating patient.
  • Patient in exclusion period (determined by a previous or a current study).
  • Patient under guardianship or trusteeship.
  • Patient under the protection of justice or deprived of liberty.
  • Patient in situation of emergency.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Enhetens gjennomførbarhet
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Studere

The CVS-Notifier SaMD reminds surgeons to time-out to check the CVS before the division of the cystic duct.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Rate of CVS-Notifier SaMD related complications
Tidsramme: From the day of the procedure up to 30 days after surgery

The rate of CVS-Notifier SaMD related complications defined as any complications caused directly or indirectly by the device. Postoperative complication will be classified according to the Clavien-Dindo classification (Grade 1 to Grade 5).

From the day of the procedure up to 30 days after surgery

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Rate of intraoperative time-out
Tidsramme: The day of the procedure

The rate of intraoperative time-out is defined as a pause in surgical activities lasting at least 2 seconds before clipping and cutting the cystic duct or the cystic artery.

The day of the procedure
Rate of CVS implementation
Tidsramme: The day of the procedure

The rate of implementation of the CVS will be assessed postoperatively on surgical videos

The day of the procedure
Surgeons' acceptance
Tidsramme: The day of the procedure

Surgeons' use and acceptance of the technology will be assessed with a specifically designed survey

The day of the procedure
Patients' acceptance
Tidsramme: The day of the procedure

Patients' acceptability and expectations on the device will be assessed with a specifically designed survey

The day of the procedure

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Silvana PERRETTA, MD, PhD, Hopitaux Universitaires de Strasbourg

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

3. april 2025

Primær fullføring (Faktiske)

7. august 2025

Studiet fullført (Faktiske)

7. august 2025

Datoer for studieregistrering

Først innsendt

17. mars 2025

Først innsendt som oppfylte QC-kriteriene

24. mars 2025

Først lagt ut (Faktiske)

26. mars 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere